Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $22.38

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average rating of “Moderate Buy” by the ten analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $22.3750.

A number of equities analysts recently weighed in on the stock. UBS Group boosted their price objective on shares of enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a report on Wednesday, November 12th. Citigroup restated a “market outperform” rating on shares of enGene in a research note on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of enGene in a research report on Tuesday, October 14th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of enGene in a report on Wednesday, December 3rd. Finally, Oppenheimer restated an “outperform” rating and set a $33.00 target price (up previously from $30.00) on shares of enGene in a research note on Wednesday, November 12th.

enGene Stock Performance

Shares of ENGN stock opened at $8.77 on Tuesday. The company has a market capitalization of $566.37 million, a price-to-earnings ratio of -4.62 and a beta of -0.28. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.34 and a current ratio of 10.34. enGene has a one year low of $2.65 and a one year high of $11.14. The company’s 50-day moving average is $7.89 and its 200 day moving average is $5.79.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 18th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). Sell-side analysts expect that enGene will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On enGene

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENGN. Affinity Asset Advisors LLC purchased a new stake in enGene during the 2nd quarter valued at $280,000. Adage Capital Partners GP L.L.C. boosted its stake in shares of enGene by 2.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock worth $7,041,000 after buying an additional 41,874 shares during the last quarter. MAI Capital Management grew its holdings in shares of enGene by 11.0% in the first quarter. MAI Capital Management now owns 78,067 shares of the company’s stock worth $350,000 after acquiring an additional 7,756 shares during the period. ADAR1 Capital Management LLC purchased a new stake in enGene during the first quarter valued at $107,000. Finally, PFS Partners LLC purchased a new stake in enGene during the third quarter valued at $61,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.